Regenxbio Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. Welcome to Barclays Global Healthcare Conference. It is my -- this is Gena Wang, I cover SMid cap biotech. It is my great pleasure to introduce our -- at least in my session, last but not least, presenting company, REGENXBIO. With us today we have Ken Mills, President and Chief Executive Officer. We also have Steve Pakola, Chief Medical Officer. Ken, so maybe I will let you give a brief overview about the company, and then we dive into the Q&A.
Sounds great, Gena. Thanks to you and your team at Barclays for having us here. We're happy to be back in person. It's our first conference, at least at an investor level returning. So REGENXBIO is a gene therapy company. We are focused on AAV therapeutics as a platform. We've had a history in the field really for over 10 years since our formation. We've been a leader in pioneering the use of novel AAVs that were isolated in the lab of Jim Wilson at the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
